Focus on breast cancer (Q34710504)

4 August 2017

1 reference

title

Focus on breast cancer (English)

1 reference

4 August 2017

1 reference

1

Jose Baselga

1 reference

4 August 2017

Larry Norton

2

0 references

publication date

1 May 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

1

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

319-322

1 reference

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Positron emission tomography scanning: current and future applications

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Mechanism-based target identification and drug discovery in cancer research

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Functional genomics and the breast cancer problem

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Breast cancer genetics: what we know and what we need

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Theoretical concepts and the emerging role of taxanes in adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Cochrane review on screening for breast cancer with mammography.

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Ethnic differences in post-menopausal plasma oestrogen levels: high oestrone levels in Japanese-American women despite low weight

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Small molecule modulators of cyclin-dependent kinases for cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1535-6108(02)50066-1

7 January 2021

10.1016/S1535-6108(02)00066-1

Identifiers

DOI

1 reference

4 August 2017

1 reference